Post-Traumatic Stress Disorder (PTSD) is a mental illness related to a traumatic event. It is a severe disorder which can be chronic and can result in disabilities at the social, occupational and interpersonal level. PTSD symptoms are intrusive symptoms such as flashbacks, avoidance symptoms, and arousal symptoms (anger). PTSD is treated with pharmacotherapy and psychotherapy. However, many do not respond to these treatments. The objective of this study is to describe changes in patient-reported outcomes (PRO) and PTSD related medication consumption of military veterans with PTSD undergoing treatment with medical marijuana.
Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful
anti-inflammatory and anti-anxiety drug. However, a bell-shaped dose-response was observed,
which limits its clinical use. In the present study, In stark contrast to purified CBD, the
clone 202 (Avidekel) extract, provided a clear correlation between the anti-inflammatory and
anti-nociceptive responses and the dose, with increasing responses upon increasing doses,
making this plant medicine ideal for clinical uses.
Head Researcher: Dr R. Gallily. Zhannah Yekhtin, Lumír Ondřej Hanuš
Location: The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
Published in: Scientific Research Vol. 6 No.2, February 2015
Clinical research study that was conducted to examine whether or not cannabis brings about
clinical and bio-chemical improvement in cases of active Crohn’s disease, without the use
Head Researcher: Dr. Timna Naftali
Location: Gastroenterology Hospital: Meir Medical Center, Kfar Saba, Israel.
Published in: Clinical Gastroenterology and Hepatology, Volume 11, Issue 10, Pages 1276-1280.e1, October 2013.
A long-term observational follow-up conducted to collect data from elderly nursing home
patients that regularly use medical cannabis. The study measures parameters such as:
nutritional blood work, caloric intake, weight, prescription drug usage, sepsis, trembling,
spasticity, and quality of life measurements (mood, sleeping habits, etc.)
Head Researcher: Dr. Moshe Geitzen, Geriatrics
Location: Hadarim Nursing Home, Kibbutz Naan
Status: The results of the first two years of the follow-up were presented at two geriatrics conferences and very well received. The follow-up has been extended for a third year based on the positive feedback from the geriatrics research community
The retrospective research study was conducted by interviewing 20 patients suffering from
Crohn’s disease that were granted a license for medical cannabis treatment to measure the
effectiveness of the treatment. The study has found very positive effects on the symptoms
of the disease (number of bowel movements, quality of bowel activity, blood in stool samples,
Head Researcher: Dr. Timna Naftali, Gastroenterology
Location: Meir Medical Center, Kfar Saba, Israel.
Published in: IMAJ – The Israel Medical Association Journal, Volume 13, Pages 455-458, August 2011.
Conducted by Dr. Timna Naftali at the Meir Medical Center using the variety: Erez. The study commenced in July 2010 and will carry on through to December 2015.
Conducted by Dr. Timna Naftali at the Meir Medical Center using the variety: Avidekel. The study commenced in October 2013 and will carry on through to June 2016.
Conducted by Dr. Yahav Oron, Otolaryngology, Head and Neck Surgery at the Wolfson Medical Center using the variety: Midnight. The study commenced on November 2013 and will carry on through to June 2015.
Conducted by Professor Amos Toren, Head of Pediatric Hemato-Oncology at the Sheba Medical Center – Tel Hashomer using the varieties: Avidekel and Midnight. The study commenced in December 2013 and will carry on through to May 2015.
Conducted by Dr. Tanya Gurevich at Tel Aviv Sourasky Medical Center. The study commenced in February 2011 and will carry on through to May 2015.
Conducted by Professor Amos Toren, Head of Pediatric Hemato-Oncology at the Sheba Medical Center – Tel Hashomer. The study commenced in January 2014 and will carry on through June 2015.
Conducted by Dr. Timna Naftali at the Meir Medical Center.
A study that examines the effects of cannabis on patients with liver diseases related to Hepatitis B and C. The research will be conducted at the Ziv Medical Center in Israel.
This clinical trial will examine the effects of cannabis on dystonia and spasticity in children with neurological diseases. The clinical trial will consist of 40 patients divided into four groups which will be administered either a 6:1 or a 20:1 ratio CBD-THC oil. The study will be carried out at the Wolfson Medical Center in Israel.
A clinical trial is intended to examine the effects of Avidekel enriched with pure CBD on children with encephalopathic epilepsy. This study will include medical and research teams form 4 different hospitals in Israel.
The study will focus on the effectiveness and safety of cannabis for geriatric patients with Dementia-related behavioral problems and restlessness. Research will be carried out at the Geriatrics Department of the Sanz Medical Center (Laniado Hospital) in Israel.